# Lloyd Armbrust launches RonanRX to personalize GLP-1 dosing with AI > Source: > Published: 2026-09-02 23:36:05+00:00 # Lloyd Armbrust launches RonanRX to personalize GLP-1 dosing with AI **The two-time YC founder is pairing physician-set doses with compounded tirzepatide as regulators tighten scrutiny and telehealth rivals crowd the category.** By [RuntimeWire Staff](/author/runtimewire-staff) ยท Published Primary source: [RonanRX](https://ronanrx.com/) ## Why it matters RonanRX is testing whether software-guided, physician-controlled dosing can distinguish a compounded GLP-1 service as FDA scrutiny rises and larger telehealth providers expand access to approved drugs. [Lloyd Armbrust](https://www.armbrustusa.com/pages/ronanrx?ref=runtimewire) and [Emily Colman](https://emilycolman.com/?ref=runtimewire) launched [RonanRX](https://ronanrx.com/?ref=runtimewire), an AI-assisted care platform that uses patient data to help physicians tailor compounded GLP-1 doses rather than moving everyone through the same escalation schedule. RonanRX's public launch is current as of September 2, 2026. In an [August 4 launch account](https://www.armbrustusa.com/pages/ronanrx?ref=runtimewire), Armbrust said RonanRX's launch week began on August 4. RonanRX is listed among [Y Combinator's telehealth companies](https://www.ycombinator.com/companies/industry/telehealth?ref=runtimewire) in its Summer 2026 batch with five employees and a San Francisco location. RonanRX's website lists its corporate address in Elgin, Texas. RonanRX is Armbrust's third company as a founder. He started OwnLocal, a digital advertising software provider for local media companies, in 2008 and took it through YC's Winter 2010 batch. [YC says OwnLocal](https://www.ycombinator.com/companies/ownlocal?ref=runtimewire) now supports more than 3,300 media companies and 129,000 small businesses. Armbrust later founded Armbrust American in May 2020, when shortages exposed the United States' dependence on imported masks and other protective equipment. His move into personalized medicine began with his own treatment. Armbrust says a standard GLP-1 plan produced poor results, leading him and his physician to change the dose, timing and pace of titration. "I hadn't discovered a better drug. I'd discovered a better way to use it," he wrote in his August 4 launch account. Colman brings clinical-market experience. Her [public biography](https://emilycolman.com/?ref=runtimewire) says she has spent more than a decade working with healthcare providers and educating them about weight-loss and diabetes medications. Investor Pat Matthews said she most recently worked at Eli Lilly helping physicians with weight-management care. ### A dose curve instead of a staircase RonanRX's initial consumer offering centers on [compounded tirzepatide](https://ronanrx.com/tirzepatide?ref=runtimewire). A patient completes an intake covering medical history, goals and previous treatment. A licensed [physician](https://ronanrx.com/doctors/?ref=runtimewire) determines whether to prescribe the medication, sets a starting dose and adjusts it as the patient responds. A licensed pharmacist then verifies, prepares and releases the patient-specific prescription. RonanRX says its software can bring labs, wearable data, medical records and treatment response into a longitudinal profile. AI helps organize that information for the physician, while prescribing authority remains with the doctor. [RonanRX's website](https://ronanrx.com/?ref=runtimewire) states that no one at RonanRX can override a physician's decision and that a pharmacist controls the medication's release. The dosing argument is straightforward. Branded injection pens come in predetermined strengths, while a compounded vial can be prepared at a physician-selected concentration. RonanRX markets that flexibility as a way to start more slowly, make smaller adjustments and hold patients at a dose that remains effective rather than automatically pushing them toward the maximum. RonanRX's public launch materials do not include clinical evidence establishing that its particular approach improves patient outcomes. Its rationale combines a familiar medical principle - individual patients tolerate and respond to drugs differently - with the production flexibility available to compounding pharmacies. The platform advertises physician care for $39 per month, while [launch materials](https://www.armbrustusa.com/pages/ronanrx?ref=runtimewire) promoted GLP-1 access at $78 per month. Medication is billed separately by the dispensing pharmacy, and exact pricing varies. A physician determines the actual prescription. RonanRX says it has grown 50% week over week. Its [YC listing](https://www.ycombinator.com/companies/industry/telehealth?ref=runtimewire) does not define whether that figure measures patients, prescriptions, revenue or another unit, leaving the growth rate without a denominator. RonanRX enters a crowded market with several approaches to GLP-1 care. [Ro's ro.OS](https://ro.co/os/?ref=runtimewire) combines nationwide telehealth, laboratory and pharmacy services, while its [insurance tools](https://ro.co/os/insurance-support/?ref=runtimewire) verify benefits, estimate costs, support prior authorizations and analyze coverage data. [Found](https://joinfound.com/program?ref=runtimewire) markets MetabolicPrint, a proprietary system that it says uses biological factors to tailor medication and care plans, alongside Aimee, its 24/7 AI health companion. [Hims & Hers](https://news.hims.com/newsroom/full-range-of-fda-approved-glp-1s-available-on-hims-hers?ref=runtimewire) has shifted toward FDA-approved GLP-1 products through a collaboration with [Novo Nordisk](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?_sp=38551db9-c491-4638-a28d-0c7df1bc206b&id=916512&ref=runtimewire), including access to Wegovy and Ozempic at self-pay prices. Other rivals compete directly on compounded-drug access and service bundles. [Henry Meds says](https://henrymeds.com/treatments/weight-management/tirzepatide-tablets?ref=runtimewire) its compounded tirzepatide starts at $179 per month, including provider visits, medication, supplies and ongoing support. [Mochi Health says](https://joinmochi.com/blog/per-dose-pricing-mochi-health?ref=runtimewire) compounded tirzepatide starts at $90 at the lowest dose, with membership billed separately; the company also offers access to physicians and dietitians. These are different operating and pricing models; the available materials do not establish that any one produces better clinical outcomes. ### The pharmacy line matters RonanRX's public materials draw a specific boundary around its operation. [RonanRX's billing policy](https://ronanrx.com/payment-policy/?ref=runtimewire) identifies RonanRX as a health technology platform rather than a pharmacy. RonanRX charges for intake, scheduling and care coordination, while medication is billed separately by a dispensing pharmacy. Its materials say patients may select another pharmacy. The reviewed materials do not publicly identify the pharmacy or pharmacies responsible for fulfillment. That separation is central to RonanRX's regulatory position. RonanRX says its [physician program](https://ronanrx.com/doctors/?ref=runtimewire) follows the 503A model, under which a state-licensed pharmacy compounds a medication for an identified patient after receiving a valid prescription. RonanRX coordinates the process while the physician retains prescribing authority and the pharmacist retains release authority. The distinction arrives during a regulatory squeeze on compounded GLP-1 sellers. The [FDA has warned 30 telehealth providers](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s?ref=runtimewire) over marketing that allegedly obscured the source of compounded drugs or implied equivalence with FDA-approved products. The [FDA says it does not review compounded drugs](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss?ref=runtimewire) for safety, effectiveness or quality before marketing. The agency also says federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse-event reports to the FDA, making reports involving compounded GLP-1 drugs likely undercounts. The FDA has cited adverse-event reports associated with compounded semaglutide and compounded tirzepatide. Those reports do not by themselves establish that a compounded drug caused an event. In April 2026, the [FDA proposed excluding](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list?ref=runtimewire) semaglutide, tirzepatide and liraglutide from the list of bulk substances available to 503B outsourcing facilities. RonanRX's stated 503A, patient-specific route operates under a separate framework, though the proposal shows the direction of federal policy as approved products become more available. ### Armbrust is betting on operational control again Armbrust frames RonanRX as a continuation of his manufacturing work. Armbrust American addressed a supply chain built for scale and low cost at the expense of domestic resilience. RonanRX applies software to a different form of standardization: pharmaceutical systems designed around fixed products and average patients. RonanRX has backing from YC and Active Capital. In a [LinkedIn post](https://www.linkedin.com/posts/lloydarmbrust_pat-was-the-first-angle-investor-in-ownlocal-activity-7487991602163064832--jNr?ref=runtimewire), Armbrust said Active Capital founder Pat Matthews led RonanRX's first institutional investment. Matthews was also an early investor in OwnLocal. The post identifies the backer while keeping the check size, round structure and valuation private. That repeat relationship fits Armbrust's pitch. Matthews is backing a founder he has watched move from local-media software into physical manufacturing and now regulated healthcare operations. RonanRX gives Armbrust another supply chain to rebuild, with a harder constraint this time: every efficiency claim has to preserve the authority of the physician and pharmacist standing between the software and the patient.